000 05283nam a22004935i 4500
001 978-81-322-2837-0
003 DE-He213
005 20180206183008.0
007 cr nn 008mamaa
008 160930s2016 ii | s |||| 0|eng d
020 _a9788132228370
_9978-81-322-2837-0
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
245 1 0 _aBiomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges
_h[recurso electrónico] /
_cedited by Sanjeeva Srivastava.
264 1 _aNew Delhi :
_bSpringer India :
_bImprint: Springer,
_c2016.
300 _aXI, 118 p. 28 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aChapter 1: Exigencies of biomarker research in developing world: A focus on the dearth of biobanking resources -- Chapter 2: Geographic pervasiveness of cancer: Prospects of novel biomarker and therapeutic research in developing countries using OMICs approaches -- Chapter 3: Omics data processing and analysis -- Chapter 4: Basics of mass spectrometry and its applications in biomarker discovery -- Chapter 5: Angel Philanthropy and Crowdfunding to Accelerate Cancer Research in Developing World -- Chapter 6: Delivering on the Promise of Bioeconomy in Developing World: Link it with Social Innovation and Education -- Chapter 7: Role of proteomics in characterization of biosimilar products -- Chapter 8: Regulatory norms and intellectual property rights for biomarker research.
520 _aThis book is oriented towards post-graduates and researchers with interest in proteomics and its applications in clinical biomarker discovery pipeline. Biomarker discovery has long been the research focus of many life scientists globally. However, the pipeline starting from discovery to validation to regulation as a diagnostic or therapeutic molecule follows a complex trajectory. This book aims to provide an in-depth synopsis on each of these developmental phases attendant to biomarker ?life cycle? with emphasis on the emerging and significant role of proteomics. The book begins with a perspective on the role of biorepositories and need for biobanking practices in the developing world. The next chapter focuses on disease heterogeneity in context to geographical bias towards susceptibility to the disease and the role of multi-omics techniques to devise disruptive innovations towards biomarker discovery. Chapter 3 focuses on various omics-based platforms that are currently being used for biomarker discovery, their principles and workflow. Mass spectrometry is emerging as a powerful technology for discovery based studies and targeted validation. Chapter 4 aims at providing a glimpse of the basic workflow and considerations in mass spectrometry based studies. Rapid and aptly targeted research funding has often been deemed as one of the decisive factors enabling excellent science and path breaking innovations. With theneed for sophistication required in multi-omics research, Chapter 5 focuses on innovative funding strategies such as crowdfunding and Angel philanthropy. Chapter 6 provides the latest advances in education innovation, the premise and reality of bioeconomy especially in a specific context of the developing world, not to mention the new concept of ?social innovation? to link biomarkers with socially responsible and sustainable applications. Chapter 7, in ways similar to biomarkers, discusses the biosimilars as a field that has received much focus and prominence recently due to their immense potential in clinical and pharmaceutical innovation literatures. The broader goal post-biomarker discovery is to translate their use in clinics. However, the road from bench-to-bed side is arduous and complex that is subject to oversight from various national and international regulatory bodies. Chapter 8 underscores these regulatory science considerations and provides a concise overview on intellectual property rights in biomarker discovery. Thus, this book contributed by eminent biomarker scientists, clinicians, translational researchers and social scientists holistically covers the various facets of the biomarker discovery journey from ?cell to society? in developing world. The lessons learned and highlighted here are of interest to the life sciences community in a global and interdependent world.
650 0 _aMedicine.
650 0 _aCancer research.
650 0 _aDrug resistance.
650 0 _aInfectious diseases.
650 0 _aProteomics.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aProteomics.
650 2 4 _aInfectious Diseases.
650 2 4 _aDrug Resistance.
700 1 _aSrivastava, Sanjeeva.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9788132228356
856 4 0 _zLibro electrónico
_uhttp://148.231.10.114:2048/login?url=http://dx.doi.org/10.1007/978-81-322-2837-0
912 _aZDB-2-SBL
942 _cLIBRO_ELEC
999 _c226146
_d226146